1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Roche PD-L1 Bladder Cancer Filing Set For 2016; Investors Hope For Earlier

 
• By Jessica Merrill

With limited treatment options available for bladder cancer, being first to market with a paradigm-changing PD-1/PD-L1 inhibitor in the indication could be a big commercial opportunity.

Roche is stepping up its plans for its PD-L1 antibody, MPDL3280A, in bladder cancer, targeting a regulatory filing in 2016 as the race heats up to bring the first cancer immunotherapy to market for the challenging oncology indication.

Whether or not an opportunity for an earlier filing might exist, based on positive early data and high unmet need, is still uncertain, but Chief Operating Officer-Pharmaceuticals Daniel O’Day allowed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D